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registry study for children (“KiProReg”) at WPE. Initial 
findings are presented. 
 
Material and Methods: Between September 2013 and 
September 2015, data on 138 children (78 males, 60 females, 
aged 0.9-17.9 years (median 5.7 years)) were prospectively 
collected in KiProReg at WPE. Diagnoses were CNS tumours 
(n=73), sarcomas (n=59), extracranial germ cell tumors (n=3) 
and others (n=3), respectively. Treatment sites were brain 
(n=72), head and neck including base of skull (n=38), spine 
(n=15), or pelvis (n=13). In 73.9% of the patients, 
macroscopic residual disease was present before PT. The 
median total dose of PT was 54.0 Gy (range 29.8-74.0 Gy). 
Only two patients had a mixed beam technique. Due to the 
very young age, sedation was necessary in 55.1% of children. 
Concurrent chemotherapy was applied in 54.3% of children. 
Side-effects were classified according to Common 
Terminology Criteria for Adverse Events (CTCAE) V4.0 grading 
system. 
 
Results: Median follow-up (FU) since first diagnosis was 1.2 
years (range 0.3-16.3 years). PT was well tolerated. No or 
only mild to moderate acute side-effects (grade 1 to 2) were 
documented in the majority of children (n=116). During PT, 
acute grade 3 side-effects were observed for blood/bone 
marrow (n=21), gastrointestinum (n=8) or as general disorders 
(n=3) as well as anorexia (n=1) when compared to baseline. 
Acute grade 4 side-effects during PT were only seen for 
blood/bone marrow (n=9). In 77 children, information on 
toxicity three months after PT is available. Only few patients 
presented with grade 3 or 4 toxicities, predominantly for 
blood/bone marrow (grade 3 n=7, grade 4 n=2). Seven of 
them had received chemotherapy after PT. So far, 17 
patients failed due to recurrence or progression (local n=5; 
systemic n=12). Six of them (4.3%) have died so far, all due 
to disease. 
 
Conclusion: Initial prospective data from WPE registry 
suggest good feasibility with only mild or moderate side-
effects in the majority of children even when administering 
high doses at critical sites. Higher-grade side-effects primary 
for blood and bone marrow are obviously influenced by 
concurrent chemotherapy. Early local control rates achieved 
with PT are promising so far. However, longer FU is needed 
to analyze long-term outcome and late effects. 
 
OC-0249  
Five-year clinical outcomes after dose-escalated image-
guided proton therapy for prostate cancer 
C. Bryant
1University of Florida Proton Therapy Institute, Radiation 
Oncology, Jacksonville- Florida, USA 
1, W. Mendenhall1, B. Hoppe1, R. Henderson1, R. 
Nichols1, C. Morris1, C. Williams1, Z. Su1, Z. Li1, N. 
Mendenhall1 
 
Purpose or Objective: To report clinical outcomes for 
patients treated with image-guided proton therapy for 
localized prostate cancer. 
 
Material and Methods: Under institutional review board 
approval, the medical records of 1,215 men enrolled either 
on a prospective protocol or an outcomes tracking study 
treated for localized prostate cancer with proton therapy at 
our institution between 2006 and 2010 were reviewed. 
Ninety-eight percent of patients received 78 Gy (RBE) or 
higher; 15% received androgen deprivation therapy (ADT). 
Five-year freedom from biochemical progression (FFBP), 
distant metastasis-free survival, and cause-specific survival 
rates are reported for each risk group. Prospectively 
collected patient-reported quality-of-life data and high-grade 
toxicities are reported. A multivariate analysis was 
performed to identify clinical predictors of biochemical 
failure. 
 
Results: The median follow-up was 5.5 years. The 5-year 
FFBP rates were 99%, 94%, and 74% in low-, intermediate-, 
and high-risk patients, respectively. Actuarial 5-year rates of 
late grade 3 gastrointestinal and genitourinary toxicity were 
0.6% and 2.4%, respectively. Median International Prostate 
Symptom Scores (IPSS) before treatment and at >4 years 
after treatment were 7 and 7. Median changes in EPIC scores 
between baseline and 4+ years of follow-up were minimal in 
the bowel, urinary irritative/obstructive, and urinary 
incontinence summary domains. 
 
Conclusion: Image-guided proton therapy provided excellent 
biochemical control rates for patients with localized prostate 
cancer. Patient-reported quality of life outcomes are 
favorable and actuarial rates of high-grade toxicity were low 
following proton therapy. 
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Purpose or Objective: Reirradiation of non resectable local 
recurrence, after previous full course of radiotherapy, is 
extremely challenging. Particle therapy may theoretically be 
the ideal tool for re-irradiation thanks to its complete sparing 
of large volumes of non target tissues already irradiated to 
low-medium dose with conformal X-ray based techniques. We 
report CNAO experience, in terms of acute toxicity and early 
response to hadrontherapy, in patients with head and neck, 
skull-base and sacral local relapse, re-irradiated with carbon 
ions or protons. 
 
Material and Methods: Since February 2013 to February 
2015, 70 patients ( M/F = 41/29) underwent hadrontherapy in 
CNAO as re-irradiation. Site of disease was head and neck in 
52 patients cancer, sacrum in 12 patients, skull – base in 4 
patients and brain in 2 cases. The histologies were: squamous 
cell carcinoma ( 21 pts), adenoid cystic carcinoma (18 pts), 
chordoma (7 pts), other sarcoma (6 pts), adenocarcinoma (7 
pts), meningioma ( 4 pts), others (7 pts). Sixty-two patients 
had been treated with Carbon Ions, the rest (8 pts) with 
protons. Average age was 59 ( range 31 – 78). Previous 
radiotherapy doses ranged between 54 to 76 Gy ( with 
conventional fractionation) and 20 to 28 Gy ( with 
hypofractionation). Mean prescription dose was 61.7 Gy [RBE] 
( 32.5 – 64), mean dose per fraction was 2.4 Gy [RBE] ( 2 – 
4.5). Early toxicity was evaluated during, at the end and 
within 90 days after radiotherapy (RT). Patients were also 
followed up for late toxicity and radiologic response every 
three months after RT with magnetic resonance (MRI) and 
clinical evaluation.  
 
Results: Acute toxicity was mild with no G4 event. At the end 
of treatment 26 pts (37%) had G0 toxicity; 27 pts (38%) had 
G1 toxicity; 16 pts (23%) had G2 toxicity and only 1 pts (1%) 
had G3 mucositis. At three months this favorable profile was 
maintained; FU average 9 months ( range 3 – 24 ). Only one 
patient had G4 toxicity detected at 3 months (unilateral 
blindness due to intentional irradiation of one optic nerve 
beyond tolerance dose). Only 3 patients had G3 toxicity: skin 
fistula and osteoradionecrosis, 6 months after RT and 
cerebral edema ( requiring medical treatment) 9 months 
after RT. The patient with longest FU (24 months), has late 
toxicity G1 (hearing impairment). At the time of analysis 11 
patients had died of progressing disease (PD), 6 and 9 months 
progression free survival were 83% and 72% respectively. 
 
Conclusion: Hadrontherapy as reirradiation allows good dose 
distribution with optimal sparing of already irradiated organs 
at risk. Due to mild acute toxicity hadrontherapy may be 
considered safe and well tollerated. Longer follow up is 
needed to confirm the efficacy and the late side effects. 
 
